Peripheral arterial occlusive disease
Not yet recruitingEfficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization
Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization
- Disease:Peripheral arterial occlusive disease
- Substances:Regn7508Regn9933+1
Poland- Participants:18–64 years · 65+ years
- Substances:Regn7508
- Sponsor:Regeneron Pharmaceuticals Inc.












